Stelara Biologic Approved for Crohn's Disease
October 4th 2016The FDA recently approved Janssen's ustekinumab (Stelara) for the treatment of moderate to severe active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, as well as those who failed or were intolerant to treatment with one or more TNF blockers.
Read More
USP Updates Medicare Model Guidelines for Part D Benefit
October 4th 2016The U.S. Pharmacopeial Convention (USP) has posted for public comment its recommended revisions to the USP Medicare Model Guidelines (USP MMG) " a classification system that supports formulary development for medications covered under Medicare Part D benefits
Read More
Citing EpiPen® Outcry, NCPA Seeks Hearing on PBMs
October 3rd 2016The National Community Pharmacists Association (NCPA) has written to the congressional committee that recently questioned the manufacturer of the EpiPen® about dramatic price hikes, and encouraged the panel's leaders to schedule a hearing examining pharmacy benefit manager (PBM) corporations at the center of prescription drug prices
Read More
The Academy of Managed Care Pharmacy today kicks off AMCP Nexus 2016 with a wide variety of educational sessions and policy discussions covering such hot topics as managing the specialty drug spend, treating opioid abuse and communicating off-label health care economic information.
Read More